Bu-Shu Xu

Bu-Shu Xu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
YQYi Que
Yi Que
WXW Xiao
W Xiao
BXBu-Shu Xu
Bu-Shu Xu
XWXizhi Wen
Xizhi Wen
DWDs Weng
Ds Weng
XZXing Zhang
Xing Zhang
Well-designed clinical trials are of great importance in validating novel treatments and ensuring an evidence-based approach for sarcoma. This study aimed to provide a comprehensive landscape of the characteristics of metastatic or advanced sarcoma clinical trials using the substantial resource of the ClincialTrials.gov database. We identified 260,755 trials registered with ClinicalTrials.gov in the last 20 years, and 277 of them were eligible for inclusion. The baseline characteristics were ascertained for each trial. The trials were systematically reviewed to validate their classification into 96 trials registered before 2008 and 181 trials registered between 2008 and 2017. We found that in the last decade, metastatic and advanced sarcoma trials were predominantly phase II-III studies (p = 0.048), were more likely to be ≥2 arms (17.7% vs 35.3%, respectively; p = 0.007), and were more likely to use randomized (13.5% vs 30.4%; p = 0.002) and double-blinded (2.1% vs 9.4%; p = 0.024) assignment than trials registered before 2008. Furthermore, in the last 10-year period, metastatic sarcoma trials were more likely to be conducted in Asia. Treatment involving target therapy and immunotherapy were more common (71.8% vs 37.5%; p < 0.001) than in previous years. Our data showed provocative changes in the sarcoma landscape and demonstrated that the incidence of clinical trials with target therapy and immunotherapy is increasing. These findings emphasize the desperate need for novel strategies, including target therapy and immunotherapy, to improve the outcomes for patients with advanced sarcoma.

4 January 2026 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
RHRunkun Han
Runkun Han
DZDenghan Zhang
Denghan Zhang
SBShenrui Bai
Shenrui Bai
YMYifei Ma
Yifei Ma
BXBu-Shu Xu
Bu-Shu Xu
AZAo Zhang
Ao Zhang
As immune checkpoint inhibitors (ICI)-based combination therapies are increasingly explored for treating NK/T-cell lymphoma (NKTCL), there is a critical cl